Preliminary results of a clinical trial (NCT03602157) investigating the safety and activity of this approach in 10 R/R HL and CD30+ CTCLs previously treated with brentuximab vedotin showed that 75% of HL patients achieved CR while 1 of 2 CTCL patients achieved stable disease as best response [104]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.